Medtronic (NYSE:MDT) today said it won expanded approval from the FDA for the Protégé GPS peripheral stent it acquired along with Covidien earlier this year.
The Protégé GPS self-expanding stent is already approved for use in the superficial femoral and subclavian arteries. The new approval covers its use in treating stenotic lesions in the common and external iliac arteries, Medtronic said.
Medtronic paid $50 billion for Covidien in January. Covidien itself acquired the Protégé GPS when it paid $2.3 billion for Ev3 back in 2010.
The Protégé GPS device is an open-lattice design cut from a nitinol tube that, once deployed, reaches a pre-set diameter to prop open the occluded vessel.
“The Protégé GPS self-expanding peripheral stent system is designed to enhance delivery, deployment and visibility during peripheral vascular procedures," aortic & peripheral vascular medical director Dr. Mark Turco said in prepared remarks. "This new indication will provide physicians with enhanced device options when treating complex iliac artery disease."
The post PAD: Medtronic wins expanded FDA nod for Protégé GPS stent appeared first on MassDevice.
